Kelly Yoo | Precision Medicine | Best Scholar Award

Dr. Kelly Yoo | Precision Medicine | Best Scholar Award

Kelly Yoo at Stanford University | United States

Dr. Kelly H. Yoo is a physician-scientist specializing in neurosurgery and neuro-oncology, currently conducting postdoctoral research at Stanford University. Her work bridges translational neuroscience, radiosurgery, and artificial intelligence in clinical applications. She has authored numerous peer-reviewed articles and case studies on stereotactic radiosurgery, spinal disorders, and brain metastases. Dr. Yoo has received multiple international awards and fellowships for her academic excellence and research leadership. As a committed member of professional organizations and advisory boards, she contributes to global health, clinical innovation, and medical education. Her research efforts aim to improve patient outcomes through technology-enhanced, precision-targeted therapies.

Publication Profile 

Scopus

Education 

Dr. Kelly Yoo earned her International Baccalaureate Diploma and graduated. She later obtained her MD with top distinction and completed her Doctorate (Dr. med., magna cum laude) from Heidelberg University School of Medicine. Her academic path included rigorous clinical, research, and methodological training. She completed multiple advanced certifications, including GCP, IRB, and Clinical Trial Investigator courses. She studied Fundamental Neuroscience for Neuroimaging at Johns Hopkins University and holds licenses and fellowships from institutions in Germany and the U.S., further enhancing her global medical and scientific competency.

Experience 

Dr. Yoo currently serves as a postdoctoral fellow at Stanford University, focusing on clinical and translational research in neurosurgery. She completed a clinician-scientist residency track in Baden-Württemberg and has worked across Europe and North America in academic medical centers. She is active in multiple professional societies, including AANS, CNS, and EANO. Dr. Yoo has held leadership roles in Stanford’s postdoc community and initiated several mentorship and international programs. Her academic career includes significant contributions to radiosurgical research and spinal navigation, leveraging both clinical experience and data-driven methodologies to explore innovative therapeutic solutions.

Awards and Honors 

Dr. Kelly Yoo has received numerous prestigious accolades, including the SPARK at Stanford Grant Award, Wu Tsai Neurosciences Interdisciplinary Fellowship, and multiple scholarships from the German Academic International Network (GAIN). She was also awarded the E-Fellows Gifted Education Scholarship and earned top academic distinctions from Heidelberg University and the International Baccalaureate program. She has consistently ranked in the top percentile across educational stages and received first-place honors in international mathematics competitions. Her recognitions reflect a long-standing commitment to academic excellence, scientific innovation, and leadership in neuroscience, medicine, and global health initiatives.

Research Focus 

Dr. Yoo’s research primarily centers on stereotactic radiosurgery, neuro-oncology, spinal disorders, and the integration of AI and neuroimaging into surgical planning and treatment. She investigates the clinical applications of advanced radiological techniques in treating recurrent and metastatic brain and spinal tumors. Her recent work explores synergistic effects between radiosurgery and immunotherapy and the cost-effectiveness of neurosurgical interventions. She also contributes to studies on spinal navigation, robotic-assisted surgery, and PET/MRI-guided interventions. Her interdisciplinary focus aims to enhance precision medicine and outcome prediction models in neurosurgery by blending clinical insight with computational innovation.

Publication Top Notes

Suspected and surgically managed cauda equina syndrome nationwide: epidemiological trends and socioeconomic factors influencing access to care

Trends in Sacroiliac Joint Fusion Costs and Utilization in the Privately Insured Population

Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Dr Kanwaljit Rana,Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India, India

Dr. Kanwaljit Rana 🧬📊 is a health researcher specializing in computational biology and big data analytics for disease diagnosis and health outcome prediction. Holding a Ph.D. in Biotechnology from GADVASU, India (2022), Dr. Rana integrates large-scale clinical, biological, and omics data using machine learning for precision medicine. With research experience at ICGEB and PGIMER, he has developed bioinformatics pipelines for genomics and predictive health analytics. His expertise spans AI-driven diagnostics, wearable health tech, and big data automation. A published scientist and GATE-qualified scholar, Dr. Rana continues to innovate in health data science and computational medicine. 🚀

Publication Profile

Google scholar

Education

Dr. Kanwaljit Rana 🎓 holds a Ph.D. in Biotechnology from Guru Angad Dev Veterinary and Animal Sciences University (GADVASU), India (2022). With a strong academic foundation, he previously earned a Master’s degree in Biotechnology from HNB Garhwal University, Srinagar. His expertise lies in cutting-edge biotechnological research, contributing to advancements in veterinary and animal sciences 🧬🔬. Passionate about innovation and scientific discovery, Dr. Rana continues to explore new frontiers in biotechnology, striving to make a meaningful impact in the field. His dedication to research and development reflects his commitment to scientific excellence and progressive learning

Professional Experience

Dr. Kanwaljit Rana 🎓 is a dedicated Research Associate at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (Feb 2024 – Aug 2024), where he conducts advanced bioinformatics analysis 🧬, integrating genomics and metagenomics data for disease characterization. Previously, at PGIMER, Chandigarh (Sep 2022 – Jan 2023), he developed automated workflows for tuberculosis meningitis diagnosis 🏥. His research journey includes roles at Punjab Agricultural University (PAU), Ludhiana, and Swami Vivekanand Faculty of Technology & Management, specializing in molecular breeding 🌱 and agricultural biotechnology. He is also a QC Freelancer at Cactus Communications since October 2024 ✍️.

Awards

Dr. Kanwaljit Rana 🎓 is a highly accomplished researcher, having qualified GATE Biotechnology in both 2020 and 2022 🏆, showcasing his expertise in the field. His dedication to innovative research earned him the Best Poster Award 🥇 for his work on “Boon of Cow Curd Consumption” at the National Webinar on Cowpathy and Animal Health (2021) 🐄🧪. His contributions to biotechnology and health sciences continue to make a significant impact, blending traditional knowledge with modern scientific advancements. Dr. Rana remains committed to groundbreaking research and advancements in biotechnology and health sciences 🔬📚

Research Focus

Dr. Kanwaljit Rana’s research primarily focuses on computational genomics 🧬, bioinformatics 🖥️, and veterinary genetics 🐶. His work involves biocomputational analysis of microRNAs, genome assembly, and ancestry studies, particularly in indigenous dog breeds like the Gaddi dog. His expertise extends to genome sequencing, phylogenetics, and the application of programming languages like Python, R, and MATLAB for data analysis. His contributions to veterinary science include genetic insights into animal breeding, evolution, and conservation. Through his interdisciplinary approach, Dr. Rana advances animal genomics, computational biology, and veterinary research, impacting both genetic conservation and bioinformatics applications in animal sciences.

Publication Top Notes

Mr. Syed Luqman Ali|Bioinformatics|Best Researcher Award

Mr. Syed Luqman Ali|Bioinformatics|Best Researcher Award

Mr. Syed Luqman Ali at Abdul wali khan university mardan,Pakistan

PROFILE  

 

Google scholar

Summary🎓

Passionate and goal-oriented researcher with expertise in biochemistry, computational biology, and bioinformatics. Skilled in vaccine and drug design, transcriptomics, genomics, and omics approaches. Proficient communicator and problem-solver with a commitment to impactful research.

Education📚

MPhil in Biochemistry
Abdul Wali Khan University, Mardan
Thesis: Ferroptosis-related genes and their therapeutic potential in pancreatic ductal adenocarcinoma.

BS in Biochemistry
Abdul Wali Khan University, Mardan
Thesis: Transcriptome analysis of Artemisia argyi for secondary metabolites against SARS-CoV-19.

Diploma in Digital Information Technology
Board of Technical Education, Peshawar

Technical Skills💻

Expertise in computational modeling, pharmacophore modeling, molecular docking, RNA-seq analysis, and omics approaches. Proficient in tools such as SnapGene, Cytoscape, DAVID, and KEGG databases.

Teaching Experience📘

Skilled in curriculum development and delivering lectures on biochemistry, vaccine design, and computational biology at the undergraduate level.

Research Interests🔬

Cutting-edge vaccine and drug design, cancer biomarker identification, molecular mimicry, and phylogenetic analysis. Dedicated to advancing personalized medicine and understanding biological diversity.

With a multidisciplinary approach and a passion for discovery, I am driven to make meaningful contributions to science and healthcare!

🎓Publication 

Illuminating the Frontier of Drug Discovery: Unleashing the Power of Bioinformatics for Unprecedented Breakthroughs

  • Authors   : Ali Awais, Ullah Waseef, Adil Kashif 
  • Journal    :International Journal of Molecular Biotechnological Research
  • Year         :2023

Mutational screening of GDAP1 in dysphonia associated with Charcot-Marie-Tooth disease: clinical insights and phenotypic effects

  • Authors   : Uzma Manzoor, Awais Ali, S Luqman Ali, Omneya Abdelkarem, Sumaira Kanwal, Saqer S Alotaibi, Alaa Baazeem, Aliya Baiduissenova, Ayaz Yktiyarov, Azraida Hajar, Abay Olzhabay
  • Journal    : Journal of Genetic Engineering and Biotechnology
  • Year         :2023

Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against Leishmania tropica – a hierarchical subtractive proteomics and …

  • Authors   :Sara Aiman, Abbas Ahmad, Azmat Ali Khan, Amer M Alanazi, Abdus Samad, Syed Luqman Ali, Chunhua Li, Zhiguang Ren, Asifullah Khan, Saadullah Khattak
  • Journal    : Frontiers in Immunology
  • Year         :2023

Genomic annotation for vaccine target identification and immunoinformatics-guided multi-epitope-based vaccine design against Songling virus through screening its whole genome …

  • Authors   :S Luqman Ali, Awais Ali, Abdulaziz Alamri, Aliya Baiduissenova, Marat Dusmagambetov, Aigul Abduldayeva
  • Journal    :Frontiers in Immunology
  • Year         :2023

Currently trending and futuristic biological modalities in the management of different types of diabetes: A comprehensive review

  • Authors   : A ALi, U Manzoor, SL Ali, MD Marsool, PK Parida, AD Marsool, NL Swathi
  • Journal    :J Popul Ther Clin Pharmacol
  • Year         :2023

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Assist Prof Dr. Lili Xu, at China Pharmaceutical University,China

Author Profile

🎓 Academic and Professional Background:

Lili Xu, Ph.D., earned her degree in Pharmaceutical Chemistry and Biology from China Pharmaceutical University in 2017. She conducted postdoctoral research at the same institution until July 2021 when she was promoted to Associate Researcher. She leads two projects funded by the National Natural Science Foundation of China and two by the Natural Science Foundation of Jiangsu Province. With over 40 SCI papers and six patents, she’s received awards like the Shimadzu Young Scholar, Gold Prize of the Macedonia Invention, and Silver Prize of the Geneva Invention Award.

🔬 Research and Innovations:

Completed/Ongoing Research Projects:

  • National Natural Science Foundation of China, General Program: Screening, design, and synthesis of novel inhibitors that interfere with the formation of NEK7-NLRP3 inflammasome complexes and their application in the treatment of acute and chronic inflammation-related diseases (82173675), 2022.01~2025.12, RMB 550,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, Youth Program: Discovery, design, synthesis, and exploration of NLRP3 inflammasome-targeted inhibitors for the treatment of non-controllable inflammatory disorders (81803354). 2019.01~2021.12, RMB 210,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, Youth Program: Design and synthesis of NLRP3-targeted inhibitors based on skeleton reconstruction strategy, and exploration of their therapeutic effects on non-controllable inflammatory disorders (BK20180564). 2018.07~2021.06, RMB 200,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, General Program: Discovery, design, synthesis, and activity evaluation of novel inhibitors targeting TLR4-MD2 immune-inflammatory pathway for drug addiction treatment (BK20231480). 2023-07-01~2026-06-30, RMB 100,000, principal investigator, ongoing.
  • China Postdoctoral Science Foundation, General Program: Discovery, optimization, activity evaluation, and mechanistic studies of ULK1 inhibitors (2017M620232), 2018.01~2021.01, RMB 80,000, principal investigator, completed.

 

  • Fundamental Research Funds for the Central Universities, Key Program: Discovery and validation of novel oxadiazole-based anti-inflammatory target proteins using proteomics and molecular probe technology, 2021.01~2022.12, RMB 150,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, General Program: Discovery of ubiquitin E3 ligase Cbl-b inhibitors based on substrate-binding crucial features and exploration of their application in tumor immunotherapy (82173680), 2022.01~2025.12, RMB 550,000, ongoing, participating.

 

  • National Natural Science Foundation of China, General Program: Discovery of targeted inducers of tau protein degradation conjugates based on ubiquitin E3 ligase Keap1 and exploration of their therapeutic application in Alzheimer’s disease (81773581), 2018.01~2021.12, RMB 620,000, completed, participating.

 

  • National Natural Science Foundation of China, Youth Program: Research on the application of GNN-based Raman hotspot regulation method in drug-target interaction (81803485), 2019.01~2021.12, RMB 210,000, completed, participating.

🏭 Consultancy/Industry Projects:

  • Institutional commissioned project: Detection of drugs in urban wastewater in Jiangyin City, commissioned by the Jiangyin Public Security Bureau, RMB 69,100, principal investigator, ongoing.
  • Industry commissioned project: Joint laboratory for drug detection between China Pharmaceutical University and Jiangsu Kangda Detection Technology Co., Ltd. (co-build laboratory), RMB 200,000, principal investigator, ongoing.

📚 Books Published (ISBN):

Currently, no books have been published.

💡 Patents Published/Under Process:

As the first inventor, Lili Xu has obtained 5 granted invention patents; as the fourth inventor, she has obtained 1 granted invention patent. Patent numbers: ZL201911146468.0, ZL202110442073.6, ZL202010483840.3, ZL201910366733.X, ZL202210071005.8, ZL202210146811.7.

.

🎓Publication Top Noted:

Paper Title : Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl
    • Authors:Jun Huang, Xing-Xing Fan, Jiaxi He, Hui Pan, Run-Ze Li, Liyan Huang, Zebo Jiang, Xiao-Jun Yao, Liang Liu, Elaine Lai-Han Leung, Jian-Xing Hee
    • Journal: Oncotarget
    • Year:2016
    • Citations : 86

     

Paper Title :The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD
  • Authors: Chu, F.-X., Wang, X., Li, B., Xu, L.-L., Di, B.
  • Journal: Inflammation Research
  • Volume: In Press
  • Issue: In Press
  • Year: 2024
Paper Title : Protein-protein interactions and related inhibitors involved in the NLRP3 inflammasome pathway
  • Authors: Ma, Z.-Y., Jiang, C., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 14–28
  • Year: 2023
Paper Title :Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors
  • Authors: Ye, T., Tao, W.-Y., Chen, X.-Y., Di, B., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 1–13
  • Year: 2023
Paper Title : A light-up fluorescence probe for wash-free analysis of Mu-opioid receptor and ligand-binding events
  • Authors: Jia, Y., Xu, L., Wang, L., Yan, F., Hu, C.
  • Journal: Analytica Chimica Acta
  • Volume: 1261
  • Pages: 341220
  • Year: 2023